The study will use NMA to analyze and evaluate the best treatment regimen of chemotherapy combined with different doses of IL-2 maintenance therapies for AML, and provide an objective basis and medication reference for clinical diagnosis and treatment. Here, IL2 is linked to acute myeloid leukemia.